Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma.

Mikulski, Stanislaw M

Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. [electronic resource] - Journal of clinical oncology : official journal of the American Society of Clinical Oncology Jan 2002 - 274-81 p. digital

Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

0732-183X

10.1200/JCO.2002.20.1.274 doi


Aged
Antineoplastic Agents--adverse effects
Female
Humans
Infusions, Intravenous
Male
Mesothelioma--drug therapy
Middle Aged
Multivariate Analysis
Proportional Hazards Models
Ribonucleases--adverse effects
Statistics, Nonparametric
Survival Rate